Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4A0NP)

Drug Name

SOPHORICOSIDE Drug Info

Synonyms

Sophoricoside; 152-95-4; UNII-J0407L5MGM; J0407L5MGM; CHEMBL486626; 5,7-dihydroxy-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one; 5',7'-Dihydroxy-4'-glucosyloxyisoflavone; 4-(5,7-dihydroxy-4-oxo-4H-chromen-3-yl)phenyl beta-D-glucopyranoside; 5,7-dihydroxy-3-(4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)phenyl)-4H-chromen-4-one; 3-{4-[(2S,4S,5S,3R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)(2H-3,4,5,6-tetrahydr opyran-2-yloxy)]phenyl}-5,7-d

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5321398
CAS Number: CAS 152-95-4
TTD Drug ID: DM4A0NP

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin-5 (IL5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benralizumab	DM7P1J4	Asthma	CA23	Approved	[2]
Mepolizumab	DMW2GEJ	Severe asthma	CA23	Approved	[3]
Reslizumab	DM0AUCH	Severe asthma	CA23	Approved	[4]
GSK3511294	DMWKSFY	Asthma	CA23	Phase 3	[5]
Depemokimab	DMG9VHN	Asthma	CA23	Phase 3	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-5 (IL5)	TTPREZD	IL5_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Design and synthesis of novel hydroxyalkylaminomethylchromones for their IL-5 inhibitory activity. Bioorg Med Chem. 2010 Jul 1;18(13):4625-9.
2	Benralizumab a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity a novel approach for the treatment of asthma
3	Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563. Drugs R D. 2008;9(2):125-30.
4	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
5	A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022 Feb;88(2):702-712.